2023 - Research.com Best Scientist Award
2023 - Research.com Medicine in France Leader Award
2023 - Research.com Immunology in France Leader Award
2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in France Leader Award
2022 - Research.com Immunology in France Leader Award
2019 - Member of the National Academy of Sciences
2017 - Member of the National Academy of Medicine (NAM)
2016 - Presidential Award, Clinical Immunology Society
2015 - Japan Prize for the proposal of the concept of gene therapy and its clinical applications.
2014 - Robert Koch Prize
2000 - Grand Prix scientifique de la Fondation NRJ, Institut de France
Member of the European Molecular Biology Organization (EMBO)
Alain Fischer focuses on Immunology, Immunodeficiency, Transplantation, Severe combined immunodeficiency and Internal medicine. In most of his Immunology studies, his work intersects topics such as Genetic enhancement. His studies deal with areas such as Ectodermal dysplasia, Phenotype, X-linked lymphoproliferative disease, Nonsense mutation and ORAI1 as well as Immunodeficiency.
Alain Fischer has included themes like Stem cell and Histocompatibility in his Transplantation study. His Severe combined immunodeficiency research is multidisciplinary, incorporating perspectives in Cancer research, Disease, Bone marrow and Virology. His studies in Internal medicine integrate themes in fields like Gastroenterology, Endocrinology and Surgery.
His primary areas of study are Immunology, Transplantation, Severe combined immunodeficiency, Immunodeficiency and Hematopoietic stem cell transplantation. His research in Immunology intersects with topics in Genetic enhancement and Stem cell. The concepts of his Genetic enhancement study are interwoven with issues in Combined immunodeficiencies and Bioinformatics.
The Severe combined immunodeficiency study combines topics in areas such as Cancer research, Bone marrow and Virology. His study focuses on the intersection of T cell and fields such as Molecular biology with connections in the field of Cytotoxic T cell, Somatic hypermutation, DNA repair, Genetics and Immunoglobulin class switching. The various areas that Alain Fischer examines in his Immune system study include Gene and Lymphocyte.
Alain Fischer spends much of his time researching Immunology, Immune system, Pediatrics, T cell and Internal medicine. His research investigates the connection between Immunology and topics such as Phenotype that intersect with problems in Mutation. As a part of the same scientific family, Alain Fischer mostly works in the field of Immune system, focusing on Myeloid and, on occasion, Common variable immunodeficiency.
Alain Fischer has researched Pediatrics in several fields, including Hematopoietic stem cell transplantation, Hemophagocytic lymphohistiocytosis, Retrospective cohort study, Intensive care and Primary immunodeficiency. His research in Hematopoietic stem cell transplantation tackles topics such as Severe combined immunodeficiency which are related to areas like Stem cell. His T cell research incorporates themes from B cell, Cancer research, Cell growth and Germline.
Alain Fischer mainly investigates Immunology, Immune system, T cell, Internal medicine and Interferon. Immunology and Germline mutation are commonly linked in his work. His work deals with themes such as Osteopetrosis, Hematopoietic stem cell and Single Center, which intersect with Immune system.
His T cell research is multidisciplinary, relying on both Cancer research, X-linked severe combined immunodeficiency, Genetic enhancement, Progenitor cell and Lymphocyte. His biological study spans a wide range of topics, including Gene mutation and Copy-number variation. Alain Fischer focuses mostly in the field of Interferon, narrowing it down to topics relating to Tumor necrosis factor alpha and, in certain cases, Alpha interferon, Viral load, Interleukin 6, Inflammation and Chemokine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
S. Hacein-Bey-Abina;C. Von Kalle;C. Von Kalle;M. Schmidt;M. P. McCormack.
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
Marina Cavazzana-Calvo;Salima Hacein-Bey;Geneviève De Saint Basile;Fabian Gross.
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
Salima Hacein-Bey-Abina;Christof Von Kalle;Manfred Schmidt;Françoise Le Deist.
The New England Journal of Medicine (2003)
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
Jérôme Hadjadj;Nader Yatim;Laura Barnabei;Aurélien Corneau.
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Salima Hacein-Bey-Abina;Alexandrine Garrigue;Gary P. Wang;Jean Soulier.
Journal of Clinical Investigation (2008)
Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
F. Rieux-Laucat;F. Le Deist;C. Hivroz;I. A. G. Roberts.
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).
Patrick Revy;Taro Muto;Yves Levy;Frédéric Geissmann.
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Nathalie Cartier;Salima Hacein-Bey-Abina;Cynthia C. Bartholomae;Gabor Veres.
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Marina Cavazzana-Calvo;Emmanuel Payen;Olivier Negre;Gary Wang.
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Salima Hacein-Bey-Abina;Françoise Le Deist;Frédérique Carlier;Cécile Bouneaud.
The New England Journal of Medicine (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: